Polymyositis is a rare autoimmune disorder characterized by chronic inflammation of the muscles, leading to progressive weakness and fatigue. According to Tippawan Onchan et al., 2024, patients with idiopathic inflammatory myopathies (IIMs), including polymyositis, have lower survival rates than the general population, with early mortality ranging between 7.8% and 45%. Current therapies focus on immunosuppressants and corticosteroids, while emerging treatments in the pipeline aim at targeted biologics and gene therapies. According to the polymyositis pipeline analysis by Expert Market Research, growing research, increased awareness, and advancements in precision medicine are expected to drive significant growth in the coming years.
Major companies involved in the polymyositis pipeline analysis include Argenx, Pfizer, and others.
Leading drugs currently in the pipeline include PF-06823859, PN-101, and others.
The pipeline is set for significant growth, driven by advanced biologics and targeted therapies. Increased clinical trials and strategic collaborations are accelerating development and expanding treatment options.
The Polymyositis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into polymyositis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for polymyositis. The polymyositis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The polymyositis pipeline landscape will include an analysis based on efficacy and safety measures outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with polymyositis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to polymyositis.
Read more about this report - Request a Free Sample
Polymyositis is a rare inflammatory muscle disease characterized by chronic muscle inflammation and progressive weakness, primarily affecting the shoulders, hips, and neck. The exact cause remains unknown, though immune system dysfunction is believed to trigger muscle fiber damage. Symptoms often include fatigue, difficulty swallowing, and reduced mobility, significantly impacting daily activities.
Polymyositis treatment focuses on suppressing inflammation and improving muscle strength. Standard therapies include corticosteroids, immunosuppressants, and physical therapy to manage symptoms and prevent disease progression. PF1801, a novel long-acting glucagon-like peptide-1 receptor agonist, received FDA Orphan Drug designation in September 2021. It shows potential in improving muscle function in rare inflammatory myopathies.
According to Tippawan Onchan et al., 2024, patients with idiopathic inflammatory myopathies (IIMs) exhibit lower survival rates compared to the general population, with early mortality ranging from 7.8% to 45%. Incidence rates vary across regions, reported at 7.7 cases per million in Asia and 2.18 cases per million in Israel. Overall, the global incidence ranges from 1.16 to 19 cases per million per year, with a prevalence of 2.4 to 33.8 per 100,000.
This section of the report covers the analysis of polymyositis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The polymyositis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 40%, covers a major share of the total polymyositis clinical trials. It is followed by phase I at 36.73%, and phase III at 18.37%. This distribution indicates a robust pipeline, with a significant number of candidates advancing through early and mid-stage trials. The progression of these therapies holds promise for enhancing treatment options and improving patient outcomes in polymyositis.
The drug molecule categories covered under the polymyositis pipeline analysis include small. The polymyositis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for polymyositis. Immune-targeted therapies are gaining traction in the polymyositis drug pipeline to address high unmet needs. For instance, AstraZeneca initiated the JASMINE Phase III trial in September 2024 to evaluate Saphnelo (anifrolumab) in patients with idiopathic inflammatory myopathies, including polymyositis. This therapy selectively inhibits type I interferon signaling, aiming to reduce muscle inflammation and improve patient outcomes, offering a disease-specific alternative to broad immunosuppressants and corticosteroids.
The EMR report for the polymyositis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed polymyositis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in polymyositis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for polymyositis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of polymyositis drug candidates.
PF-06823859, sponsored by Pfizer, is an investigational drug being evaluated in a Phase 3 study for adults with active idiopathic inflammatory myopathies, including polymyositis and dermatomyositis. The study is examining how PF-06823859, administered as an intravenous infusion every four weeks, affects muscle strength, inflammation, and overall safety. This monoclonal antibody is designed to target immune-mediated muscle damage, aiming to improve mobility and reduce disease-related muscle weakness over a 48-week treatment period.
PN-101, sponsored by Paean Biotechnology Inc., is an innovative allogeneic mitochondrial therapy derived from umbilical cord–derived mesenchymal stem cells. This Phase 2 trial is evaluating the efficacy and safety of PN-101 in patients with refractory polymyositis or dermatomyositis. The study is examining improvements in disease activity using IMACS-TIS at Week 12 compared with a placebo. PN-101 is administered as a single intravenous dose, aiming to restore cellular function and reduce inflammation in affected muscles.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Polymyositis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for polymyositis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into polymyositis collaborations, regulatory environments, and potential growth opportunities.
Upto 20% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share